Table 3.

AHSG reactivity in cancer patients according to clinicopathologic variables

Factors (n)AHSG negative (%)AHSG positive (%)P*
Age in y0.182
≤40 (19)5 (29.4)14 (21.9)
41-50 (35)9 (52.9)26 (40.6)
>51 (27)3 (17.6)24 (37.5)
T stage0.895
T1 (35)7 (41.2)28 (43.8)
T2 (44)10 (58.8)34 (53.1)
T3 (1)01 (1.6)
T4 (1)01 (1.6)
N stage0.465
N0 (46)8 (47.1)38 (59.4)
N1 (23)6 (35.3)17 (26.6)
N2 (8)2 (11.8)6 (9.4)
N3 (4)1 (5.9)3 (4.7)
TNM stage (AJCC 6th)0.554
I (28)4 (23.5)24 (37.5)
II (40)10 (58.8)30 (46.9)
III (13)3 (17.6)10 (15.6)
IV (0)00
Estrogen receptor status0.989
Negative (38)8 (47.1)30 (46.9)
Positive (43)9 (52.9)34 (53.1)
Progesterone receptor status0.656
Negative (42)8 (47.1)34 (53.1)
Positive (39)9 (52.9)30 (46.9)
Her2 status0.736
    0 (48)11 (64.7)37 (57.8)
    1+ (11)1 (5.9)10 (15.6)
    2+ (16)4 (23.5)12 (18.8)
    3+ (6)1 (5.9)5 (7.8)
  • * Significance was tested using Pearson χ tests.